2000
Creation of Inserm Transfert, the private subsidiary of Inserm.
Our history
Since its creation in 2000, Inserm Transfert has been continuously discovering innovations from the Inserm laboratories and developing them among industrialists.
It was in 1980 when the Bayh-Dole Act in the United States opened the path to the creation of a value creation office and TTO (Technology Transfer Office). France followed two years later with the “guiding and programming law for technological research and development”: this introduced the principals of value creation and researchers being an objective on a similar scale to that of knowledge acquisition. In 1984 the law on higher education, strengthened the 1982 law enabling the formation of value creation departments within Universities.
In 1999, the Allègre law made it possible for universities and researchers to create a start-up and to submit patents.
Following this last law, Inserm decided, in 2000, to create Inserm Transfert. The company has advanced in a rich, stimulating and complex human health innovation ecosystem at the interface between the academic and industrial world and with local, national and international components.
-
-
2003
Creation of a dedicated team helping researchers to respond to EU collaborative research projects calls.
-
2005
Creation of Inserm Transfert Initiative, a dedicated seed money fund for life sciences.
-
2006
Inserm Transfert has been given the management of the entire promotion and transfer of knowledge emerging from the Inserm research laboratories to the industrial world, from invention disclosure to industrial partnerships and startups incorporation.
-
2009
Inserm creates a proof of concept investment fund entirely managed by Inserm Transfert.
-
2010 - 2012
Inserm Transfert is ISO 9001:2008 certified for its European and international project management activities and its intellectual Property activity.
-
2015
Definition and setting up of a strategic road map Inserm Transfert 2020: In parallel to the strategic plan Inserm 2020.
-
2017
Inserm Transfert has launched in 2017 this Pathway for Pre-entrepreneurship to support researchers/inventors that aspire to become involved in entrepreneurship and to help them become ”Enlighted founders” (“Fondateurs Eclairés”).
-
2018
Inserm Transfert is ISO 9001 v2015 certified for all its technology transfer activities. Set up of the strategic road map from Inserm Transfert "FRS 2018-2028".
-
2019
Inserm Transfert is a well-recognized company worldwide in economic and societal value creation in human health. Laureate of French Tech Seed with the HHSF Consortium (Human Health Startup Factory).
-
2020
Inserm Transfert is 20 years old. Inserm Transfert maintains ISO 9001 v2015 certification for the quality management of all its activities. Inserm Transfert co-constructs the PBS Consortium Laureate of 2nd call for proposals SIA "SATT-Incubators-Accelerators" from Investments for the future program (PIA).
-
2021
New strategic road map Inserm Transfert 2021-2025
-
2022
Inserm Transfert maintains ISO 9001 v2015 certificate for all its technology transfer activities. Inserm Transfert moves to PariSanté Campus.
-
2023
Inserm Transfert is committed to the France 2030 investment plan and the 4th Future Investment Programme (PIA4) through 3 national acceleration strategies to accelerate the dynamics innovation in healthcare.